Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | LMNA | P02545 | 5/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941882 | 1.00 | ALDH1A1 (0.70) | ALDH1A1LMNAPOLBGAAHPGD | |
| SCHEMBL3058461 | 0.86 | LMNA (0.64) | ALDH1A1LMNAPOLBGAAHPGD | |
| SCHEMBL4943598 | 0.83 | SMN1; SMN2 (0.76) | ALDH1A1LMNAPOLBGAAHPGD | |
| SCHEMBL19657077 | 0.79 | SLC9A1 (0.64) | ALDH1A1LMNAPOLBGAAHPGD | |
| SCHEMBL5842477 | 0.78 | ALDH1A1 (0.65) | ALDH1A1HPGDMAPTNPSR1SLC9A1 | |
| SCHEMBL29941707 | 0.77 | ALDH1A1 (0.77) | ALDH1A1HPGDMAPTNPSR1TDP1 | |
| SCHEMBL3875107 | 0.77 | ALDH1A1 (0.77) | ALDH1A1HPGDMAPTNPSR1TDP1 | |
| SCHEMBL27669475 | 0.77 | ALDH1A1 (0.55) | ALDH1A1LMNAPOLBGAAHPGD | |
| SCHEMBL3616840 | 0.75 | ALDH1A1 (0.57) | ALDH1A1LMNAPOLBGAAHPGD | |
| SCHEMBL3616838 | 0.75 | ALDH1A1 (0.57) | ALDH1A1LMNAPOLBGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307394-B1 | SULPHONAMIDES AS VANILLOID RECEPTOR ANTAGONIST | AMOREPACIFIC CORP (KR) | 2012-09-26 | — | — | EP | claimed |
| JP-2011526625-A | — | — | 2011-10-13 | — | — | JP | claimed |
| WO-2010002209-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2010-01-07 | — | — | WO | claimed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | claimed |
| EP-3515880-B1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF ENCODED LIBRARIES | HITGEN INC (CN) | 2023-05-10 | — | — | EP | disclosed |
| EP-3226858-B1 | IMIDAZOLE-BASED ANTIMICROBIAL AGENTS | PROCOMCURE BIOTECH GMBH (AT) | 2021-02-03 | — | — | EP | disclosed |
| EP-2259377-B1 | SOLAR CELL | SHARP KK (JP) | 2020-06-03 | — | — | EP | disclosed |
| US-20200149034-A1 | Methods and Compositions for Synthesis of Encoded Libraries | HITGEN INC. (CN) | 2020-05-14 | — | — | US | disclosed |
| US-10456379-B2 | Imidazole-based antimicrobial agents | PROCOMCURE BIOTECH GMBH (AT) | 2019-10-29 | — | — | US | disclosed |
| US-10322110-B2 | Imidazole-based antimicrobial agents | PROCOMCURE BIOTECH GMBH (AT) | 2019-06-18 | — | — | US | disclosed |
| US-10314820-B2 | Imidazole-based heterocyclic compounds | PROCOMCURE BIOTECH GMBH (AT) | 2019-06-11 | — | — | US | disclosed |
| EP-2632460-B1 | THIOPHENE DERIVATIVES FOR USE IN THE TREATMENT OF TUBERCULOSIS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2018-02-28 | — | — | EP | disclosed |
| US-6500840-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2002-12-31 | — | — | US | disclosed |
| US-6492385-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY GLOBAL INTELLECTUAL PROPERTY | 2002-07-11 | — | — | US | disclosed |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| WO-2002015662-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002017358-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002016355-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC) ACETYLCHOLINE RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10456379-B2 | Imidazole-based antimicrobial agents | TLR5, NISCH, SLC11A2 | ALDH1A1 1629/4885LMNA 4548/4885POLB 1637/4885 |
| US-10322110-B2 | Imidazole-based antimicrobial agents | ARG1, SLC11A2, IKZF3 | ALDH1A1 1211/4885LMNA 4362/4885POLB 3215/4885 |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | ALDH1A1 130/4885LMNA 2140/4885POLB 637/4885 |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PARK7, CYP3A7, UGT2B7 | ALDH1A1 267/4885LMNA 3219/4885POLB 344/4885 |
| US-10314820-B2 | Imidazole-based heterocyclic compounds | MIF, SLC11A2, TLR5 | ALDH1A1 370/4885LMNA 4294/4885POLB 1569/4885 |
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | ALDH1A1 130/4885LMNA 2140/4885POLB 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.